MétaCan
Menu
Back to cohort
Record W4362664139 · doi:10.1136/bmjopen-2022-068363

Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial)

2023· article· en· W4362664139 on OpenAlexaff
C. David Mazer, Niloufar Siadati-Fini, Johannes Boehm, Felix Wirth, Andrej Myjavec, Craig Brown, Jay L. Koyner, Andreas Boening, Daniel T. Engelman, Tobias E. Larsson, Ronny Renfurm, Benoît de Varennes, Nicolas Noiseux, Matthias Thielmann, André Lamy, Maxime Laflamme, Thilo von Groote, Claudio Ronco, Alexander Zarbock

Bibliographic record

VenueBMJ Open · 2023
Typearticle
Languageen
FieldMedicine
TopicAcute Kidney Injury Research
Canadian institutionsUniversité du QuébecInstitut universitaire de cardiologie et de pneumologie de QuébecMcGill UniversitySaint John Regional HospitalHamilton Health SciencesUniversity of TorontoPopulation Health Research InstituteUniversité de MontréalSt. Michael's Hospital
Fundersnot available
KeywordsMedicineInterim analysisPlaceboRenal functionDosingClinical trialAdverse effectInternal medicineIncidence (geometry)Acute kidney injurySurgeryPathologyAlternative medicine

Abstract

fetched live from OpenAlex

INTRODUCTION: Acute kidney injury (AKI) is a common complication after cardiac surgery (CS) and is associated with adverse short-term and long-term outcomes. Alpha-1-microglobulin (A1M) is a circulating glycoprotein with antioxidant, heme binding and mitochondrial-protective mechanisms. RMC-035 is a modified, more soluble, variant of A1M and has been proposed as a novel targeted therapeutic protein to prevent CS-associated AKI (CS-AKI). RMC-035 was considered safe and generally well tolerated when evaluated in four clinical phase 1 studies. METHODS AND ANALYSIS: This is a phase 2, randomised, double-blind, adaptive design, parallel group clinical study that evaluates RMC-035 compared with placebo in approximately 268 cardiac surgical patients at high risk for CS-AKI. RMC-035 is administered as an intravenous infusion. In total, five doses will be given. Dosing is based on presurgery estimated glomerular filtration rate (eGFR), and will be either 1.3 or 0.65 mg/kg.The primary study objective is to evaluate whether RMC-035 reduces the incidence of postoperative AKI, and key secondary objectives are to evaluate whether RMC-035 improves postoperative renal function compared with placebo. A blinded interim analysis with potential sample size reassessment is planned once 134 randomised subjects have completed dosing. An independent data monitoring committee will evaluate safety and efficacy data at prespecified intervals throughout the trial. The study is a global multicentre study at approximately 30 sites. ETHICS AND DISSEMINATION: The trial was approved by the joint ethics committee of the physician chamber Westfalen-Lippe and the University of Münster (code '2021-778 f-A') and subsequently approved by the responsible ethics committees/relevant institutional review boards for the participating sites. The study is conducted in accordance with Good Clinical Practice, the Declaration of Helsinki and other applicable regulations. Results of this study will be published in a peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: NCT05126303.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.016
metaresearch head score (Gemma)0.014
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.060
Threshold uncertainty score0.201

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0160.014
Meta-epidemiology (narrow)0.0060.003
Meta-epidemiology (broad)0.0100.003
Bibliometrics0.0010.002
Science and technology studies0.0030.004
Scholarly communication0.0030.003
Open science0.0040.001
Research integrity0.0070.007
Insufficient payload (model declined to judge)0.0600.014

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.200
GPT teacher head0.524
Teacher spread0.324 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueBMJ OpenSame topicAcute Kidney Injury ResearchFrench-language works237,207